• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Bui Lynne A.

    11/9/23 7:55:53 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HILS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bui Lynne A.

    (Last) (First) (Middle)
    C/O THARIMMUNE, INC.
    1200 ROUTE 22 EAST, SUITE 2000

    (Street)
    BRIDGEWATER NJ 08807

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tharimmune, Inc. [ THAR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/07/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options (right to buy) $0.1577 11/07/2023 A 25,000 (1) 11/07/2033 Common stock 25,000 $0 25,000 D
    Explanation of Responses:
    1. On November 7, 2023, the Reporting Person was granted options ("Options") to purchase up to 25,000 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant.
    /s/ Randy Milby as Attorney-In-Fact for Lynne Bui 11/09/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HILS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HILS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HILS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/18/23 10:04:37 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/4/23 4:15:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bui Lynne A.

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    11/9/23 7:55:53 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

    Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new t

    9/22/23 8:30:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

    Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple rec

    9/11/23 11:51:49 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

    Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023. Event: H.C. Wainwright Presentation On-DemandDate: September 11th, 2023Time: 7:00am ETRegistration: Link *Please note that Company presentation

    9/8/23 2:30:00 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Leadership Updates

    Live Leadership Updates

    View All

    Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

    Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma (NASDAQ:HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients' lives,

    7/10/23 8:47:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

    BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company finance, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its or

    5/15/23 8:47:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    SEC Filings

    View All

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    2/8/24 4:05:29 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    12/12/23 4:15:16 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events (Amendment)

    8-K/A - Tharimmune, Inc. (0001861657) (Filer)

    12/11/23 6:15:17 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/18/23 10:04:37 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/4/23 4:15:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hillstream BioPharma Inc. (Amendment)

    SC 13G/A - Tharimmune, Inc. (0001861657) (Subject)

    2/14/24 4:00:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hillstream BioPharma Inc.

    SC 13G - Tharimmune, Inc. (0001861657) (Subject)

    12/7/23 4:00:10 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care